Poor
Not Aligned
Patient Risk:
Low
Summary
Most naming/prescription and cross-manufacturer/INN claims are not supported by the provided label text. The label supports only that the product LANOXIN contains digoxin and is supplied as tablets; it does not substantiate the broader assertions made.
Category Scores
Accurate Statements
The medication name stays digoxin even when it is sold in different formulations (for example, tablets or oral solution).
11 DESCRIPTION: discusses LANOXIN (digoxin) and supplies digoxin as tablets for oral administration; uses 'digoxin' as the drug substance name in the context of this product. Does not address oral solution or explicitly state naming consistency across formulations.
Unsupported Statements
Digoxin’s generic name is digoxin.
Provided label text identifies the product as LANOXIN (digoxin) but does not explicitly state 'digoxin' is the generic name.
Digoxin is the non-brand (INN) name used to identify the drug across generic and brand products.
Provided label text does not discuss INN/nonproprietary naming conventions or cross-brand/generic usage.
The medication name stays digoxin even when it is sold in different formulations (for example, tablets or oral solution).
Label text provided describes tablets; it does not mention oral solution or explicitly state that the name stays 'digoxin' across formulations.
The brand name changes by manufacturer, but the generic name does not.
No statement in provided label text addresses manufacturer-specific brand changes or generic-name consistency.
On prescriptions, the drug is usually written as digoxin (generic name), plus a strength.
Label text provides tablet strengths but does not describe prescription-writing conventions.
On prescriptions, the drug is usually written as digoxin (generic name), plus the formulation (tablet, elixir/solution, etc.).
Label text provided discusses tablets; it does not describe prescription nomenclature or elixir/solution formulations.
Contradictions
Important Omissions
Any label-supported details about dosage/administration beyond tablet supplies (e.g., dosing regimens), or safety/contraindications relevant to prescribing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims concern naming/prescription conventions rather than clinical dosing or safety. However, several claims are not supported by the provided label text, which could affect accurate identification and prescribing communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple assertions about generic/INN naming conventions, cross-formulation naming consistency (including oral solution), brand changes by manufacturer, and prescription-writing conventions are not supported by the provided label section.
Suggested Improvement
Limit statements to what the provided label text explicitly supports (e.g., that LANOXIN contains digoxin and that it is supplied as digoxin USP tablets for oral administration with specified strengths). Remove or qualify claims about INN/generic conventions, prescription formatting, and other formulations not mentioned in the label excerpt.